Na Julaị 16, akwụkwọ akụkọ mba ụwa kachasị elu bụ Nature Medicine bipụtara data nyocha na SHR-A1904, otu ọgwụ mgbochi-ọgwụ (ADC) nke na-elekwasị anya na claudin 18.2 (CLDN18.2), maka ọgwụgwọ nke kansa afọ dị elu ma ọ bụ kansa gastroesophageal junction (GC/GEJC). Ndị nchọpụta ahụ mere nnwale ahụike nke mbụ n'ime mmadụ, nke nwere usoro atọ, iji nyochaa irè nke SHR-A1904 na mmadụ 95 a gwọrọ ọrịa kansa G/GEJ dị elu nke CLDN18.2.
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Claudin-18 isoform 2 (CLDN18.2), protein njikọ siri ike nke a na-egosipụta na epithelium afọ na-abụghị nke na-egbu egbu ma na-ekpughere ya n'elu mkpụrụ ndụ tumor n'oge mgbanwe kansa, bụ ihe mgbaru ọsọ ọgwụgwọ na-ekwe nkwa maka kansa gastric na gastroesophageal junction (G/GEJ). SHR-A1904 bụ njikọ antibody-drug nke nwere CLDN18.2-targeting monoclonal antibody, DNA topoisomerase I inhibitor payload na njikọ peptide nke a na-ekewapụ.
N'oge a na-ebelata ọnụọgụ ọgwụ (0.6–8.0 mg kg−1), a hụrụ ihe ndị na-egbochi oke ọgwụ n'ime ndị ọrịa abụọ nọ na 4.8 mg kg−1 (klas 3 febrile neutropenia na ọkwa 3 mụbara bilirubin ọbara) na n'otu onye ọrịa nọ na 6.0 mg kg−1 (ọnya mucosal afọ nke klas 3). Erughị oke ọgwụ a na-anabata, a họrọkwara 6.0 mg kg−1 na 8.0 mg kg−1 maka mgbasa nke pharmacokinetic na arụmọrụ. Ihe ndị na-adịghị mma nke ọgwụgwọ pụtara na ndị ọrịa 95 niile, nke kachasị bụ anaemia (72 (75.8%)), ọgbụgbọ (64 (67.4%)), hypoalbuminemia (61 (64.2%)) na mbelata ọnụọgụgụ mkpụrụ ndụ ọbara ọcha (56 (58.9%)). Na mgbakwunye, ndị ọrịa 59 (62.1%) nwetara ihe ndị na-adịghị mma nke metụtara ọgwụ na ọkwa 3 ma ọ bụ karịa. Akọpụtaghị ọnwụ metụtara ọgwụgwọ ọ bụla. N'ime ndị ọrịa a na-enyocha mmeghachi omume ha, ọnụego nzaghachi ebumnuche akwadoro bụ 24.2% (95% oge ntụkwasị obi (CI), 11.1–42.3) na 6.0 mg kg−1 na 25.0% (95% CI, 12.1–42.2) na 8.0 mg kg−1. Nduzi nke etiti enweghị ọganihu bụ ọnwa 5.6 (95% CI, 3.0–6.9) na 6.0 mg kg−1 na ọnwa 5.8 (95% CI, 3.0–8.6) na 8.0 mg kg−1. Na mmechi, SHR-A1904 gosipụtara profaịlụ nchekwa a na-achịkwa ma na-agba ume ọrụ mgbochi-tumor na ndị ọrịa nwere CLDN18.2-positive G/GEJ, nke chọrọ nyocha ọzọ.
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Oge ozi: Julaị-24-2025